Skip to main content
PREFER
  • About
  • Partners
  • Case studies
  • Publications
  • Stakeholders
  • News
  • Contact
  • Recommendations
PREFER
  • About
  • Case studies
  • Events
  • Stakeholders
  • News
  • Partners
  • People
  • Publications
  • Contact
  • Recommendations
PREFER Partners
Listen
  • About
  • Case studies
  • Events
  • Stakeholders
  • News
  • Partners
  • People
  • Publications
  • Contact
  • Recommendations

PREFER Partners

PREFER has 31 partners. The consortium is co-ordinated by Uppsala University, and managed together with Novartis that acts as project leader.

Academic institutions

  • Uppsala University (Co-ordinator)
  • Erasmus University Rotterdam
  • European Institute of Oncology
  • University Medical Centre Utrecht
  • University of Birmingham
  • University of Erlangen
  • University of Leuven
  • University of Newcastle upon Tyne

Patient organisations

  • European Cancer Patients Coalition (ECPC)
  • European Patient Forum (EPF)
  • International Alliance of Patients’ Organizations (IAPO)
  • Muscular Dystrophy UK (MDUK)

HTA-Bodies

  • Belgian Health Care Knowledge Centre (KCE)

Small and medium sized enterprises

  • MindBytes
  • COLLABORATE

Pharmaceutical Industry

  • Novartis Pharma (Project Leader)
  • AbbVie
  • Actelion Pharmaceuticals
  • Amgen
  • Astellas Pharma Europe
  • AstraZeneca
  • Bayer
  • CSL Behring
  • Eli Lilly and Company
  • Janssen
  • Merck KGaA
  • MSD
  • Pfizer
  • Roche
  • Sanofi
  • Takeda Development Centre Europe

PREFER project partners

Print

Contact us

contact@imi-prefer.eu

communications@imi-prefer.eu

Follow us on twitter: @IMI_PREFER or YouTube

Subscribe to our newsletter

Disclaimer: This website and its contents reflects the PREFER project's view and not the view of IMI, the European Union or EFPIA.


 

Shortcuts

About PREFER

Our Stakeholders

Partners

ProjectPlace login

Dissemination proposal form

Accessibility report for imi-prefer.eu

PREFER

The Patient Preferences in Benefit-Risk Assessments during the Drug Life Cycle (PREFER) project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 115966. This Joint Undertaking receives support from the European Union's Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA).

This site is hosted by Uppsala University

This website uses cookies to make your website experience as good as possible.